Compare VanEck Gold Miners ETF (GDX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Johnson & Johnson — how do they compare? VanEck Gold Miners ETF trades at $71.49, while Johnson & Johnson trades at $250.23 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while VanEck Gold Miners ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | JNJ | |
|---|---|---|
52-Week High | $115.84 | $267.24 |
52-Week Low | $51.15 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $71.42, down 4.62% with bearish technical signals from moving averages. The fund faces competition from lower-fee gold ETFs while offering mining equity exposure with higher volatility. Recent portfolio changes include the addition of Aya Gold & Silver, potentially enhancing diversification. Technical indicators show neutral oscillators but overall bearish momentum with key support at $70.
The outlook remains cautious as gold miners navigate gold price volatility and fee competition. Upside potential exists if gold rebounds, but investors face risks from sector underperformance relative to physical gold. Analyst views are mixed, with some seeing value in discounted valuations while others highlight structural challenges in the mining ETF space.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
